Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

NCT03435952 | Active Not Recruiting Phase 1 FDA Drug

• 2 other identifiers: 2017-0719NCI-2018-00757
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

Some tumors are difficult to treat with chemotherapy or radiation. One of the reasons is that areas of the tumor do not have many blood vessels, which makes it difficult for drugs to reach those areas. One way that researchers have recently tried to overcome this problem is by injecting special kinds of bacteria into the tumors. These bacteria have been genetically changed to remove the chemicals that are poisonous to humans, but are still able to cause tumor cells to break down and die. The idea is that these bacteria may be able to assist chemotherapy drugs in fighting cancer. The goal of this clinical research study is to find the highest tolerable dose of one of these bacterial therapies (Clostridium novyi-NT spores) that can be given in combination with pembrolizumab to patients with advanced solid tumors. The safety of this drug will also be studied, as well as whether it can help to control the disease. This is an investigational study. Clostridium novyi-NT is not FDA approved or commercially available. It is currently being used for research purposes only. Pembrolizumab is FDA approved for the treatment of melanoma and different types of head and neck and non-small cell lung cancers. It is investigational to use these drugs in combination with each other in various types of advanced cancers. The study doctor can describe how the study drugs are designed to work. Up to 18 participants will be enrolled in this study. All will take part at MD Anderson.

Conditions

Malignant Neoplasm of Breast; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Independent (Primary) Multiple Sites; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands; Malignant Neoplasms of Urinary Tract

Keywords

Pembrolizumab; Keytruda; MK-3475; SCH-900475; Clostridium Novyi-NT; C. novyi-NT; Doxycycline; Vibramycin; Periostat; Doryx; Solid tumor malignancies

Outcome Measures

Primary Outcomes (1)

• Maximum Tolerated Dose (MTD) of Intratumoral Injection of Clostridium Novyi-NT with Pembrolizumab

  MTD defined as the highest dose studied in which the incidence of DLT was less than 33%.

  6 weeks

Secondary Outcomes (1)

• Preliminary Anti-Tumor Activity of Pembrolizumab in Combination with C. novyi-NT in the Injected Tumor and an Overall Response by RECIST 1.1

  6 weeks

Study Arms (1)

Pembrolizumab + Clostridium novyi-NT

EXPERIMENTAL

Participants receive Pembrolizumab by vein over about 30 minutes on Day 0 and then every 3 weeks for up to 12 months. Clostridium novyi-NT injected into the tumor on Day 8. Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT

Drug: Pembrolizumab; Biological: Clostridium Novyi-NT; Drug: Doxycycline

Interventions

Pembrolizumab DRUG

200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.

Also known as: Keytruda, MK-3475, SCH-900475

Pembrolizumab + Clostridium novyi-NT

Clostridium Novyi-NT BIOLOGICAL

Participants given a single dose of Clostridium Novyi-NT by intratumoral injection on Day 8. Clostridium Novyi-NT administered starting with Cohort 1 at a dose of 3 x 10\^4 spores followed by dose escalation.

Pembrolizumab + Clostridium novyi-NT

Doxycycline DRUG

Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT

Also known as: Vibramycin, Periostat, Doryx

Pembrolizumab + Clostridium novyi-NT

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of an advanced solid tumor malignancy. There must be a target tumor which is measureable, palpable or clearly identifiable under ultrasound or radiographic guidance and amenable to percutaneous injection of C. novyi-NT spores. The targeted lesion must have a longest diameter \>/= 1 cm and \< 12 cm and be measurable as defined by RECIST 1.1 criteria. The target lesion must not be located in either the thoracic, abdominal or pelvic cavities or in the brain. There must be no clinical, no functional, and no radiographic evidence of bone involvement at the site of the target lesion.
• History of prior treatment with at least one line of systemic anticancer therapy, when an approved systemic therapy is available, and no curative option is available for continued treatment.
• At least 4 weeks have elapsed since the completion of major surgery, and the patient has fully recovered from this surgery and any post-surgical complications.
• Patient must have adequate organ function as indicated by the following laboratory values. Hematological: Absolute neutrophil count (ANC) \>/=1,500/mcL; Platelets \>/=100,000/mcL; Hemoglobin \>/=9g/dL or \>/= 5.6 mmol/L. Renal: Serum creatinine \</= 1.5 X upper limit of normal (ULN. Hepatic: serum total bilirubin \</= 1.5 X ULN OR Direct bilirubin \</= ULN for patients with total bilirubin levels \> 1.5 ULN; AST (SGOT) and ALT (SPGT) \</= 2.5 X ULN OR \</= 5 X ULN for patients with liver metastases. Coagulation: International Normalized ration (INR) or Prothrombin Time (PT) \</= 1.5 X ULN unless patient is receiving anticoagulant therapy as long as PT of PTT is within therapeutic range of intended use of anticoagulants; Activated partial Thromboplastin Time (aPTT) \</= 1.5 X ULN unless patient is receiving anticoagulant therapy as long as PT of PTT is within therapeutic range of intended use of anticoagulants.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Patient is at least 18 years of age.
• Patient is capable of giving informed consent.
• Female patient of childbearing potential has a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the patient to be eligible.
• Patient of childbearing potential is using either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy or to abstain from heterosexual activity throughout the study, starting with Visit 1 through 120 days after the last dose of study therapy. Approved contraceptive methods include 2 of the following barrier methods or one barrier method combined with a hormonal contraceptive: a. Intra uterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide. Spermicides or condoms alone are not an acceptable method of contraception. b. Male patients must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study therapy.
• Patient has no significant valvular heart disease (trace or mild valvular stenosis or regurgitation is allowed).
• Patient is able to stay within 45 minutes driving time of an emergency room for 28 days after dosing with C. novyi-NT.
• The patient has a caregiver for 28 days after dosing with C. novyi-NT.
• Patient has a tumor sample from C. novyi-NT planned injected tumor lesion (newly obtained biopsy) for PD-L1 and immunologic response assessments. Patients must submit the tumor sample during screening at a central pathology laboratory.

You may not qualify if:

• Patient who has had chemotherapy, radiation therapy, or biological cancer therapy within four weeks prior to the first dose of study drug, or who has not recovered to CTCAE Grade 1 or better from the AEs due to cancer therapeutics administered more than four weeks earlier.
• Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of the first dose of study drug. (A patient in the survival Follow up phase of an investigational agent where no further treatment is expected is eligible).
• Patient is on any systemic corticosteroid therapy within one week before the planned date for first dose of treatment or on any other form of immunosuppressive medication.
• Documented primary brain malignancy or brain metastases.
• Patient previously had a severe hypersensitivity reaction to treatment with another mAb.
• Patient has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Patients with hypothyroidism stable on hormone replacement will not be excluded from the study.
• Patient has an active infection requiring systemic therapy.
• Patient has known history of Human Immunodeficiency Virus (HIV) (HIV ½ antibodies).
• Patient has a known history of or is positive for Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA \[qualitative\] is detected).
• Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.
• Patient has received a live vaccine within 30 days prior to first dose.
• Patient has a foreign body which in the opinion of the treating investigator could be difficult to manage in case of infection.
• Clinically significant pleural effusion.
• Clinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than 1.0 cm at any location around the heart.
• Need for ongoing treatment with an immunosuppressive agent.

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead
• Merck Sharp & Dohme LLC: collaborator
• BioMed Valley Discoveries, Inc: collaborator

Study Sites (1)

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

• University of Texas MD Anderson Cancer Center Website

MeSH Terms

Conditions

Breast Neoplasms; Urologic Neoplasms

Interventions

pembrolizumab; Doxycycline

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Urogenital Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Urologic Diseases

Intervention Hierarchy (Ancestors)

Tetracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds

Study Officials

• Sarina Piha-Paul, MD, PHD

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

• Sarina Piha-Paul, MD

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2018
• First Posted: February 19, 2018
• Study Start: July 10, 2018
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: April 16, 2026

Record last verified: 2026-04

Locations

US (1)